MerLion secures first partner for lead drug finafloxacin
This article was originally published in Scrip
Executive Summary
The private Singapore venture MerLion Pharmaceuticals has struck the first licensing deal for its lead therapeutic candidate, the fluoroquinolone antibiotic finafloxacin.